Go Pro

Hemab Therapeutics (COAG) Institutional Ownership

Hemab Therapeutics logo
$39.40 -0.48 (-1.20%)
As of 09/11/2026 04:00 PM Eastern

Institutional Ownership Changes (13F Filings) for Hemab Therapeutics (NASDAQ:COAG)

Number of
Institutional Buyers
(last 12 months)
5
Total
Institutional Inflows
(last 12 months)
$27.77M
Number of
Institutional Sellers
(last 12 months)
0
Get COAG Insider Trade Alerts

Want to know when executives and insiders are buying or selling Hemab Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Chart & View Institutional Buying and Selling Data

COAG Institutional Buying and Selling by Quarter

Hemab Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
9/9/2026 Opaleye Management Inc.47,652$1.75M0.2%N/A0.102%
9/9/2026 The Manufacturers Life Insurance Company 18,720$688K0.0%N/A0.040%
9/9/2026 Squarepoint Ops LLC6,252$230K0.0%N/A0.013%
9/2/2026 Citadel Advisors LLC523,450$19.23M0.0%N/A1.121%
8/21/2026 Braidwell LP160,000$5.88M0.2%N/A0.343%


COAG Institutional Ownership - Frequently Asked Questions

During the previous two years, the following institutional investors and hedge funds held shares of Hemab Therapeutics shares: Citadel Advisors LLC ($19.23M), Braidwell LP ($5.88M), Opaleye Management Inc. ($1.75M), and The Manufacturers Life Insurance Company ($688K), Squarepoint Ops LLC ($230K).Learn more on Hemab Therapeutics' institutional investors.

The following institutional investors have purchased Hemab Therapeutics' stock in the last 24 months: Citadel Advisors LLC ($523.45K), Braidwell LP ($160K), Opaleye Management Inc. ($47.65K), The Manufacturers Life Insurance Company ($18.72K), and Squarepoint Ops LLC ($6.25K).

Institutional investors have bought a total of 756,074 shares in the last 24 months. This purchase volume represents approximately $27.77M in transactions.



Institutional ownership data for NASDAQ:COAG is compiled from quarterly 13F filings submitted to the U.S. Securities and Exchange Commission (SEC), with the most recent received on 9/9/2026. New 13F filings are added each quarter as they're published.
From Our Partners